Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90B1 | P14625 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464932 | 0.91 | HSP90B1 (0.76) | HSP90B1ADORA3ADORA1P2RY1ADORA2A | |
| SCHEMBL19464935 | 0.91 | HSP90B1 (0.76) | HSP90B1ADORA3ADORA1P2RY1ADORA2A | |
| SCHEMBL26934885 | 0.91 | HSP90B1 (0.76) | HSP90B1ADORA3ADORA1P2RY1ADORA2A | |
| SCHEMBL19464999 | 0.85 | P2RY1 (0.57) | HSP90B1ADORA3ADORA1P2RY1ADORA2A | |
| SCHEMBL25566630 | 0.80 | ADORA3 (0.75) | ADORA3ADORA1ADORA2ATMIGD3 | |
| SCHEMBL19464849 | 0.79 | P2RY1 (0.63) | HSP90B1ADORA3ADORA1P2RY1ADORA2A | |
| SCHEMBL25566627 | 0.78 | P2RY1 (0.51) | HSP90B1ADORA3ADORA1P2RY1ADORA2A | |
| SCHEMBL19799159 | 0.78 | HSP90B1 (0.80) | HSP90B1ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL19459913 | 0.78 | HSP90B1 (0.80) | HSP90B1ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL19807417 | 0.77 | ADORA3 (0.84) | HSP90B1ADORA3ADORA1ADORA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | SLC6A3, PNMT, CES2 | HSP90B1 3289/4885ADORA3 274/4885ADORA1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.